当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:2930.22亿  总市值:2932.43亿
流通股本:63.74亿   总股本:63.79亿

现金流量表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金15,683,728,234.1311,508,327,824.893,610,622,678.0118,567,439,285.94
收到的税费返还43,742,611.7530,038,928.34,086,874.54260,229,594.35
收到其他与经营活动有关的现金728,799,087.31606,882,363.75402,204,476.2727,342,112.4
经营活动现金流入的平衡项目0000
经营活动现金流入小计16,456,269,933.1912,145,249,116.944,016,914,028.7519,555,010,992.69
购买商品、接受劳务支付的现金837,496,649.53743,708,616.87167,321,804.541,073,321,878.61
支付给职工以及为职工支付的现金4,411,153,993.323,022,383,571.271,445,955,580.66,234,169,734.58
支付的各项税费1,071,284,318.49923,729,349.76244,715,318.231,891,336,552.16
支付其他与经营活动有关的现金5,827,463,790.934,580,079,109.671,944,952,044.689,090,918,195.41
经营活动现金流出的平衡项目0000
经营活动现金流出小计12,147,398,752.279,269,900,647.573,802,944,748.0518,289,746,360.76
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额4,308,871,180.922,875,348,469.37213,969,280.71,265,264,631.93
二、投资活动产生的现金流量:
收回投资收到的现金2,507,501,921.221,910,899,190.971,009,687,069.759,602,363,872.85
取得投资收益收到的现金89,493,013.5170,391,868.8134,465,549.44166,492,049.03
处置固定资产、无形资产和其他长期资产收回的现金净额13,232,187.474,359,0002,619,00020,212,976.52
处置子公司及其他营业单位收到的现金净额---36,045,413.27
投资活动现金流入的平衡项目0000
投资活动现金流入小计2,610,227,122.21,985,650,059.781,046,771,619.199,825,114,311.67
购建固定资产、无形资产和其他长期资产支付的现金1,370,472,925.79985,275,270.78384,785,041.221,992,177,711.16
投资支付的现金2,167,7402,167,7402,061,5107,442,647,233.57
投资活动现金流出的平衡项目0000
投资活动现金流出小计1,372,640,665.79987,443,010.78386,846,551.229,434,824,944.73
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额1,237,586,456.41998,207,049659,925,067.97390,289,366.94
三、筹资活动产生的现金流量:
吸收投资收到的现金-750,470-378,863,693.27
其中:子公司吸收少数股东投资收到的现金---378,863,693.27
取得借款收到的现金21,100,00010,000,00010,000,0001,260,000,000
收到其他与筹资活动有关的现金---159,991,787.52
筹资活动现金流入平衡项目0000
筹资活动现金流入小计21,100,00010,750,47010,000,0001,798,855,480.79
偿还债务支付的现金1,265,000,0001,260,000,0001,260,000,000-
分配股利、利润或偿付利息支付的现金1,022,662,627.2983,482,349.162,603,856.081,015,542,764.53
支付其他与筹资活动有关的现金823,380,363.12389,083,592.5212,197,109.381,102,082,925.71
筹资活动现金流出平衡项目0000
筹资活动现金流出小计3,111,042,990.322,632,565,941.661,474,800,965.462,117,625,690.24
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-3,089,942,990.32-2,621,815,471.66-1,464,800,965.46-318,770,209.45
四、汇率变动对现金及现金等价物的影响19,695,828.827,703,481.52-10,038,953.680,497,370.18
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额2,476,210,475.811,279,443,528.23-600,945,570.391,417,281,159.6
加:期初现金及现金等价物余额14,537,437,248.0814,537,437,248.0814,537,437,248.0813,120,156,088.48
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额17,013,647,723.8915,816,880,776.3113,936,491,677.6914,537,437,248.08
补充资料:
净利润-2,290,405,823.55-3,815,070,903.04
资产减值准备---146,684,220.61
固定资产和投资性房地产折旧-277,059,737.22-516,638,467.38
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-277,059,737.22-516,638,467.38
无形资产摊销-13,137,257.91-22,481,863.6
长期待摊费用摊销-42,699,513.58-66,260,667.22
处置固定资产、无形资产和其他长期资产的损失--2,607,859.52--5,473,705.52
固定资产报废损失-1,835,135.87-1,241,289.19
公允价值变动损失-27,623,041.85--76,502,527.08
财务费用-8,174,342.92-6,491,852.72
投资损失--28,587,392.24--457,335,523.59
递延所得税--197,169.31--22,107,625.03
其中:递延所得税资产减少-4,952,940.2--81,667,954.13
递延所得税负债增加--5,150,109.51-59,560,329.1
存货的减少-47,249,456.92--52,676,161.51
经营性应收项目的减少-138,974,926.23--2,284,569,087.41
经营性应付项目的增加--30,317,131.51--510,977,298.55
其他-90,051,310.37-34,980,700
现金的期末余额-15,816,880,776.31-14,537,437,248.08
减:现金的期初余额-14,537,437,248.08-13,120,156,088.48
公告日期2023-10-262023-08-192023-04-222023-04-22
审计意见(境内)标准无保留意见
TOP↑